 acelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) reported fourth quarter 2019 net sales of $3.6 million which is 49% higher than the third quarter with solid growth expected for the rest of this year. 
 we also provided an update on the commercial launch of our new noninvasive antibiotic, dSUVIA in the fourth quarter of this year. 
 we also announced the signing of a definitive agreement to acquire Tetraphase Pharmaceuticals, as well as entering into a co-promotion agreement which allows us to more quickly realize some key benefits from the transaction. 
 we expect significant revenue and cost synergies as a result of the merger which we expect to close in the second quarter of this year.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 